Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Euclidean Capital

Investor type Family Investment Office

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 31
Average round size
info
The average size of a deal this fund participated in
$76M
Portfolio companies 21
Rounds per year 2.38
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.32
Exits 2
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Artificial Intelligence
  • Medical Device
  • Software
Summary

The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Euclidean Capital performs on 16 percentage points less the average number of lead investments. The high activity for fund was in 2019. When the investment is from Euclidean Capital the average startup value is more than 1 billion dollars. The top amount of exits for fund were in 2019. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 7-8 participants. Despite the Euclidean Capital, startups are often financed by Polaris Partners, OrbiMed, GV. The meaningful sponsors for the fund in investment in the same round are Topspin Partners, The Column Group, Polaris Partners. In the next rounds fund is usually obtained by Viking Global Investors, Two Sigma Ventures, Topspin Partners.

The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Biotechnology, SaaS. Among the most popular portfolio startups of the fund, we may highlight 23andMe, Alector, ArsenalBio. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

Besides them, we counted 2 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Euclidean Capital:
Typical Co-investors
Euclidean Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Euclidean Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allianz Bayern, Germany, München
Andrew W. Mellon Foundation New York, Nyack, United States
BentallGreenOak Canada, Ontario, Toronto
Canadian Pacific Alberta, Calgary, Canada
China Fortune Holdings Limited China, Hong Kong, New Territories
China Southern Asset Management China, Guangdong, Shenzhen
Drayton Park Capital Pennsylvania, Radnor, United States
Gordon Brothers Group Boston, Massachusetts, United States
Huatu Capital Beijing, Changping, China
Liberty Advisor Group Chicago, Illinois, United States
Light Street Capital California, Palo Alto, United States
Longde Zichan China, Hangzhou, Zhejiang
Perry Creek Capital New York, New York, United States
Springboard-Harper Central, Central Region, Singapore
Stonebridge Financial Canada, Ontario, Toronto
Telmex Distrito Federal, Mexico, Mexico City
UnitedHealthcare Minnesota, Minnetonka, United States
Woven Capital Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Casma Therapeutics

Biotechnology
Health Care
Therapeutics
$46M15 Nov 2022 Cambridge, Massachusetts, United States

ArsenalBio

Artificial Intelligence
Biotechnology
Cloud Computing
$220M06 Sep 2022 South San Francisco, California, United States

April

Financial Services
FinTech
Information Technology
$30M29 Jun 2022 New York, New York, United States

Possible

Finance
Financial Services
FinTech
Software
$20M03 May 2022 Seattle, Washington, United States

DroneBase

Construction
Drones
Electronic Equipment and Instruments
Mapping Services
Media and Information Services (B2B)
Real Estate
$20M26 Oct 2021 Santa Monica, California, United States

Duality Technologies

Artificial Intelligence
Cyber Security
Software
$30M05 Oct 2021 Newark, New Jersey, United States

Ripple Foods

Food and Beverage
Food Processing
Sustainability
$60M21 Sep 2021 California, United States

Circle Pharma

Biotechnology
Clinical Trials
Health Care
Therapeutics
$66M16 Jun 2021 San Francisco, California, United States

Ribon Therapeutics

Biotechnology
Health Care
Medical Device
Therapeutics
$65M14 Jun 2021 Massachusetts, United States
News
Drone data analytics provider DroneBase nabs $20M

– DroneBase, a company providing drones as a service to capture high-resolution aerial photos, announced that it raised $20 million in a funding round led by Euclidean Capital with participation from Union Square Ventures, Upfront Ventures, Energy Transition Ventures, Hearst Ventures, Pritzker Group Venture Capital, and Valor Equity Partners.
– The company says that the funds will be put toward expansion in the renewable energy industry and other segments with “high-value” infrastructure, like commercial real estate and insurance.
– Investments in drone startups are growing as the benefits of AI applied to aerial photography become clear. For example, algorithms analyze images from drones to monitor for corrosion, pests, and even livestock health. And insurers like State Farm leverage drones for claims inspections, assessing on-the-ground damage, and emergency resources following a disaster.

Ribon Therapeutics Secures $65 Million Financing

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Euclidean Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: